Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00246467 · ClinicalTrials.gov registry record · Phase 1
One Year Study to Evaluate Three Different Adjuvanted Doses of the Recombinant Plague Vaccine (rF1 and rV Antigens)
A Phase 1 study, sponsored by PharmAthene UK Limited.
- Completed
- Registry status
- Phase 1
- Development phase
- 123
- Enrollment target
NCT00246467: Completed Phase 1 study, sponsored by PharmAthene UK Limited.
NCT00246467 is a Phase 1 study that has completed, run by PharmAthene UK Limited. The registered enrollment target is 123 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (105% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00246467, a Phase 1 study, has completed, sponsored by PharmAthene UK Limited.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 123 participants
- Enrollment target
Study Summary
One hundred and five subjects will be recruited into three groups. Each subject will receive two doses of recombinant plague vaccine at one of three dose levels (rF1 and rV recombinant antigen proteins).
Interventions
- BIOLOGICAL Alhydrogel
- BIOLOGICAL rF1 and rV protein antigens
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 123 participants |
| Start Date | 2005-10 |
| Est. Completion | 2007-04 |
| Phase | Phase 1 |
What the finished NCT00246467 record still lists
NCT00246467 is an interventional study that assigns participants to a tested intervention. The registered 123 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (105% higher).
The record links to 0 conditions, and to 2 interventions - of which Alhydrogel is the first listed.
NCT00246467 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00246467 about?
NCT00246467 is a clinical study titled "One Year Study to Evaluate Three Different Adjuvanted Doses of the Recombinant Plague Vaccine (rF1 and rV Antigens)". One hundred and five subjects will be recruited into three groups. Each subject will receive two doses of recombinant plague vaccine at one of three dose levels (rF1 and rV recombinant antigen proteins).
What is the current status of trial NCT00246467?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 123 participants. The study started on 2005-10. Estimated completion is 2007-04.
What interventions are being tested in trial NCT00246467?
The interventions under investigation include: Alhydrogel (BIOLOGICAL), rF1 and rV protein antigens (BIOLOGICAL).
Who is sponsoring clinical trial NCT00246467?
This trial is sponsored by PharmAthene UK Limited, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00246467's enrollment target sits among peer trials
123 475th of 2000 higher than 1,526 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05285891 · 123 participants · Phase 4
Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis
- NCT05334368 · 123 participants · Phase 3
Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial
- NCT06088355 · 123 participants · NA
Moderate Versus High Volume Light-Moderate Intensity Exercise for People With Moderate Parkinson's Disease
- NCT06111131 · 123 participants · NA
Ancora-SB Overtube Complete Positioning and Optical Visualization During Endoscopic Procedures
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia